Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: EC:3.4.23.15 (
renin
)
35,795
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Secretion of atrial natriuretic peptide (ANP) depends on the atrial wall distension which may be caused by ventricular pacing. This study was designed to assess the differences in plasma ANP level between
DDD
and VVI pacing. We measured ANP from venous blood samples using radio-immunoassay in patients with the sick sinus syndrome (n = 8) and atrioventricular block (n = 2) following
DDD
implantation. Measurement was made under control conditions during
DDD
and 15-180 min after the pacing mode was changed to VVI and 60 min after returning to
DDD
. Serum epinephrine (E), norepinephrine (NE),
renin
(R) and aldosterone (A) levels were also measured prior to and every 30 min after pacing mode changes. The plasma ANP concentration changed from 71.3 pg/ml (normal value) with
DDD
to 126.8 (15 min), 180.6 (30 min), 221.8 (60 min), 219.2 (90 min), 270.1 (120 min), 145.4 (150 min) and 115.1 pg/ml (180 min) with VVI. It increased markedly, then gradually decreased. It returned to the control value (66.6 pg/ml) in 60 min with
DDD
, and it reached the peak level with VVI within 60-120 min, and the peak was significantly higher than that for
DDD
. The increase related to the retrograde ventriculoatrial conduction during VVI pacing. There was no significant change in the NE, E, R and A concentrations. Systolic blood pressure decreased 15 mmHg in VVI and returned to normal by
DDD
. These results indicated that plasma ANP levels is elevated by VVI pacing, though it was not explained by ventricular pacing alone.
...
PMID:[Secretion of atrial natriuretic peptide during artificial pacing: assessments including the influence of ventriculoatrial conduction]. 130 73
A 62-year-old man arrived at our hospital with recurrence of Cushing's syndrome 14 years after successful surgery for adrenocortical carcinoma. Investigations demonstrated recurrence of a large tumor above the right adrenal area; it was found to be inoperable. The patient was treated initially with a new glucocorticoid antagonist, RU 486, and later with the adrenolytic agent mitotane (o,p'
DDD
). The latter achieved hypoadrenocorticism and a substantial reduction of tumor size. During the initial period, worsening hyperadrenocorticism resulted in a rise of atrial natriuretic factor and an inhibition of
renin
activity, consistent with an increase of cortisol and plasma volume. Changes in opposite direction were observed after treatment with mitotane.
...
PMID:Late recurrence of operated adrenocortical carcinoma: atrial natriuretic factor before and after treatment with mitotane. 252 92
Adrenocortical carcinomas are very rare tumors. The diagnosis and therapeutic results in 5 female patients are reported. In 4 cases the tumor displayed biochemical and clinical features of Cushing's syndrome, while one was an adrenocortical carcinoma with hypersecretion of aldosterone only. The mean age was 53.6 +/- 8.2 years. In all four cases with Cushing's syndrome the diagnosis was established by measurement of urinary free cortisol extraction rates and excretion rates of 17-ketogenic steroids (mean 1794.5 +/- 1968 micrograms/24 h for free cortisol and 50.5 +/- 24.9 mg/24 h for 17-ketogenic steroids), while the excretion of 17-OH-steroids was in the normal range in one case with hypercortisolism. The patient with mineralocorticoid excess showed markedly elevated plasma aldosterone levels (840 pg/ml) and undetectable plasma
renin
activity (less than 0.2 ng/ml/3 h), but normal urinary excretion rates of 17-hydroxy- and 17-ketosteroids. The adrenal lesions were localized by intravenous pyelography or sonography and by angiographic procedures, while radioscanning by 131I-cholesterol showed no uptake of activity. Unilateral adrenalectomy was performed in four cases. After appearance of hormonally active metastases o,p'
DDD
was administered as an antitumor agent in 3 patients. Two of these patients died 10 and 25 months after surgery. One patient with multiple lung metastases is still alive, with a postoperative course of more than 80 months.
...
PMID:[Diagnosis and therapy of hormonally active cancer of the adrenal cortex. Study of 5 cases]. 726 61
Effectiveness of dual-chamber pacing in patients with dilated cardiomyopathy is still controversial. Our study was performed: to select the most favorable individual atrioventricular (AV) delay; to compare hemodynamic short-term effects in each patient after 2 periods of
DDD
pacing and sinus rhythm (AV spontaneous); to assess hemodynamic long-term (1 year) effects after
DDD
pacing at optimum AV delay. In 1996, 9 patients (7 men, 2 women; mean age 69 +/- 5 years) with dilated cardiomyopathy (5 idiopathic, 4 ischemic), NYHA functional class III-IV, ejection fraction < 30%, end-diastolic volume > 60 ml/m2, mitral regurgitation +2/+3, PR interval > or = 200 ms, were enrolled. All patients were implanted with
DDD
pacemakers and monitored for: ejection fraction and end-diastolic volume (measured by echocardiography and radionuclide angiography); clinical conditions; exercise tolerance and maximum oxygen consumption (by Weber exercise protocol); neurohormonal activity (plasma
renin
, aldosterone, atrial natriuretic factor). Data were recorded: before
DDD
implantation; after 2 randomized, single-blind periods of 3 months in VVI mode (at ventricular "sentinel" rate of 50 b/min) and in
DDD
mode with the optimum AV delay, corresponding for each patient to the minimum end-diastolic volume measured by radionuclide angiography and to the highest cardiac output recorded by echocardiography; after 6 months of
DDD
pacing with most favorable AV delay. Three more patients died 6 months after (between sixth and twelfth month of follow-up), due to refractory heart failure; 1 patient dropped out because his pacemaker was programmed in VVI mode at low rate, due to intolerance of
DDD
pacing. Among the other 4 patients no clinical and laboratory parameters were significantly different after 1 year of follow-up. In conclusion,
DDD
pacing in selected patients with dilated cardiomyopathy showed disappointing results, despite a strict and laboratory monitoring;
DDD
pacing could be of major benefit in larger populations, according to Doppler mitral flow pattern: those patients with a larger A-wave amplitude could be more sensitive to
DDD
pacing than those with evidence of poor atrial systole. Moreover, biatral and/or biventricular pacing could also play a significant role.
...
PMID:[Dual-chamber DDD pacing in NYHA III-IV functional class dilated cardiomyopathy: short and middle-term evaluation]. 998 41
To study complex of pathogenetic changes arising during VVI mode single chamber ventricular pacing we temporarily (for 1 hour) switched pacing mode from dual (
DDD
) to single (VVI) chamber stimulation in 11 patients. Parameters studied were cardiac output (CO), total peripheral vascular resistance (TPVR), levels of precursors of atrial and inactive fragment of brain natriuretic peptides (pro-ANP and NT-pro-BNP, respectively), noradrenaline, aldosterone, and
renin
activity in blood plasma. Reprogramming of pacing mode was associated with 21.4% lowering of CO and 11.4% elevation of TPVR according to impedance cardiography data, and augmentation of pro-ANP secretion from 429.79 to 620.22 fmol/l. At the background of VVI pacing there was a tendency to increase of noradrenaline blood concentration without significant changes of aldosterone concentration and plasma
renin
activity.
...
PMID:[Changes of parameters of hemodynamics and systems of neurohumoral regulation in patients with implanted cardiac pacemakers after switching from DDD to VVI pacing mode]. 1715 84
The aim of the study was to determine cardiovascular drugs utilization and quality of prescribing in Croatia from 2003 to 2008. Data on the outpatient utilization of cardiovascular drugs in Croatia were collected during 2003-2008. Data on the size and number of packages, were obtained from Croatian institute for Health Insurance (CIHI). Based on the data obtained, the numbers of
DDD
and
DDD
per 1000 inhabitants per day (
DDD
/1000/day) were calculated for all cardiovascular drugs. Quality of drugs prescribing was assessing using Drug Utilization 90% (DU90%) method. Renin-angiotensin system agents showed highest share in the utilization of group C drugs, followed by calcium channel blockers. These two groups of drugs accounted for half of the overall cardiovascular drug utilization. Greatest changes were observed in the groups of
renin
-angiotensin system agents and hypolipemics. The number of drugs within DU90% segment increased between 2003 and 2008. In the same period Cost/
DDD
decreased.
...
PMID:Quality of cardiovascular drugs prescribing in Croatia 2003-2008. 2233 70